Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Leads Uncluttered Race For First Norovirus Therapy

Executive Summary

Although norovirus infections are implicated in roughly 200,000 deaths per year, there are only four candidates in clinical development, Datamonitor Healthcare notes. This may be due partly to challenges posed by the virus' strain diversity and a lack of epidemiologic data.

You may also be interested in...



Takeda Cements Norovirus Lead Through Vaccine Trial Start

Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.

Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.

Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication

Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel